Thrombosis Models Provide Efficacy Assessment for Resurgent Therapeutic Area
Over the past 10 years, we’ve worked with clients to investigate potential anti-thrombotic treatments along with those interfering with the coagulation cascade.
Frankly, up until recently the requests for these types of experiments have been relatively infrequent. It was thought we had reached a new age of discovery in coagulation therapy, with the introduction of recent antiplatelet agents.
Recent challenges have arisen with these new modalities; most notably complications from excess bleeding. Some researchers have even suggested these compounds may not replace warfarin as first line therapy.
During 2013 our laboratories have experienced a notable uptick in the requests for thrombosis models.
Recently we released data demonstrating the ‘re-introduction’ of a well-characterized mouse model of arterial thrombosis. In these mice, we produce a carotid arterial thrombus using a process that can be interrupted by efficacious test articles.
Briefly, we dose mice with either vehicle or active test article prior to administration of FeCl3 to the external surface of the carotid artery. Following this exposure to FeCl3, thrombotic occlusion of the carotid artery occurs in a matter of minutes in the untreated animal. Test article efficacy can be quantitated as alterations in coronary artery blood flow along with time to occlusion.
Models like this provide a better understanding of the biological pathways associated with thrombosis. With this knowledge in hand, a number of our clients are taking a renewed look at the compounds in their arsenals in an effort to continue addressing this critical therapeutic area.